The AIOps market was valued at $5.96 billion in 2025 and is expected to reach $20.43 billion by 2035, registering a CAGR of 13.2% over the forecast period from 2026 to 2035. The integration of AI?driven observability and AIOps capabilities is becoming a foundational driver for the global AIOps market, as enterprises seek to reduce operational toil and improve system reliability across increasingly complex hybrid and multi?cloud environments. Organizations deploying AIOps tools gain greater visibility into real?time telemetry data, enabling faster detection and automated correlation of alerts, which shortens incident resolution cycles and supports higher development throughput. This shift from reactive monitoring to predictive operations is pushing IT leaders to consolidate observability platforms and invest in unified solutions that scale with business requirements. The result is measurable improvement in operational performance and an evolving baseline for IT operations that underpins broader digital transformation goals.

Global PCB market was valued at $80.3 billion in 2025 and is projected to reach $151.8 billion by 2035, growing at a CAGR of 6.7% during the forecast period (2026-2035). Growth in electronics manufacturing output is emerging as a primary structural driver for printed circuit board adoption across multiple industries. China’s Ministry of Industry and Information Technology indicates that the electronic information manufacturing sector recorded an 11.8% increase in value-added output in 2024. This indicates strong expansion in devices such as smartphones, computing equipment, and communication hardware that require advanced PCB architectures. This expansion reflects continued investment in electronic component ecosystems and higher production volumes across Asia-Pacific, reinforcing stable demand for rigid and multilayer boards. In addition, operating revenues of major electronic manufacturing firms in China reached approximately 16.19 trillion yuan ($2.26 trillion) in 2024, demonstrating the scale of downstream industries that depend on circuit board fabrication.

Nanostructured carbon composite market was valued at $896.9 million in 2025 and is expected to reach $2,150.7 million by 2035, registering a CAGR of 9.2% during the forecast period from 2026 to 2035. Rapid expansion of electric mobility and large-scale battery manufacturing is emerging as a primary structural driver supporting growth in the nanostructured carbon composite market. Government-backed energy transition policies are accelerating battery deployment, which is increasing demand for conductive and lightweight nanocarbon materials such as graphene and carbon nanotubes. According International Energy Agency, global battery manufacturing capacity expanded by nearly 30% in 2024 to exceed 3 TWh, reflecting industrial investment aligned with electrification targets. Forecast scenarios indicate that electric-vehicle battery demand could grow more than fourfold by 2030 and almost sevenfold by 2035 compared with 2023 levels, indicating sustained material consumption across energy applications.

International express delivery market was valued at $32.6 billion in 2025 and is projected to reach $87.8 billion by 2035, growing at a CAGR of 10.5% during the forecast period (2026-2035).  Growth in digitally enabled trade is emerging as a primary structural driver shaping demand for international express delivery services. According to the United Nations Conference on Trade and Development, total global trade value exceeded $35 trillion in 2025, reflecting a year-on-year increase of about 7%, with goods trade contributing nearly $1.5 trillion of additional activity. Rising trade volumes directly translate into higher demand for fast, predictable cross-border shipping, especially for high-value and time-sensitive consignments moving through integrated logistics networks.

Immunoglobulins market was estimated at $6,998.0 million in 2025 and is expected to reach approximately $13,370.5 million by 2035, reflecting a compound annual growth rate (CAGR) of 6.8% over the forecast period from 2026 to 2035. The increasing burden of primary immunodeficiency disorders and related immune dysfunction remains one of the most significant drivers supporting long-term demand for immunoglobulin therapies. Government health agencies indicate that primary immune deficiency diseases include more than 200 conditions and affect nearly 500,000 individuals in the US alone, emphasising a sizable treated population that depends on replacement therapies such as IVIG and SCIG. Early diagnosis programs promoted by national health authorities emphasise timely treatment initiation to prevent infections and long-term complications, which directly strengthens demand for plasma-derived immunoglobulins. In addition, research supported by federal institutes suggests that around one in 1,200 individuals may be diagnosed with a primary immunodeficiency, indicating a steady expansion of the patient base requiring ongoing antibody replacement therapy.

Global immunology drug market was valued at $6,225.0 million in 2025 and is projected to reach $9,240.9 million by 2035, growing at a CAGR of 4.1% during the forecast period (2026-2035). The rising prevalence of autoimmune and inflammatory disorders represents a fundamental driver supporting expansion of the global immunology drug market. According to National Institute of Allergy and Infectious Diseases indicates that autoimmune diseases affect nearly 8% of the US population, emphasizing the growing patient pool requiring long-term therapeutic management. Centers for Disease Control and Prevention surveillance further shows that more than 53.2 million US adults reported diagnosed arthritis between 2019 and 2021, reflecting a significant disease burden linked to immunology treatment demand. Increasing incidence across indications such as rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease is strengthening clinical reliance on monoclonal antibodies, fusion proteins, and immunosuppressants.

Hereditary angioedema market was valued at $3,512.0 million in 2025 and is anticipated to reach approximately $8,421.3 million by 2035, registering a CAGR of 9.2% during the forecast period from 2026 to 2035. The hereditary angioedema market is strongly influenced by increasing diagnosis rates supported by improved genetic screening frameworks and rare disease awareness initiatives led by healthcare authorities. According to data from the US National Institutes of Health, hereditary angioedema is a rare autosomal dominant disorder caused by C1-inhibitor deficiency or dysfunction, requiring specialized diagnostic evaluation and long-term clinical management. Epidemiological assessments indicate a prevalence of nearly one case per 50,000 individuals, with some population studies reporting ranges between 1 in 50,000 and 1 in 100,000, highlighting a measurable yet historically underdiagnosed patient base. Increasing recognition among physicians and allergy specialists is contributing to earlier confirmation of cases that were previously misclassified as allergic angioedema.

Immune Checkpoint Inhibitors market was valued at $6,665.0 million in 2025 and is expected to reach $29,758.1 million by 2035, registering a CAGR of 16.2% during the forecast period from 2026 to 2035. The rising burden of cancer in the US continues to strengthen the demand outlook for immune checkpoint inhibitors, particularly across tumor types where immunotherapy has become a standard treatment approach. Increasing diagnosis rates across lung, breast, colorectal, bladder, melanoma, and kidney cancers are expanding the eligible patient population for PD-1, PD-L1, and CTLA-4 inhibitors, encouraging healthcare providers to integrate these therapies earlier within oncology care pathways. Government statistics highlight a substantial clinical load on oncology systems, reinforcing the need for advanced treatments that offer durable responses and improved survival outcomes. As pharmaceutical companies continue to expand label approvals and combination therapy strategies, the growing incidence and mortality burden directly support long-term market growth and sustained adoption of immune checkpoint inhibitors across major cancer indications.

Herbal Weight Loss Products Market was valued at $6,501 million in 2025 and is anticipated to reach $16,390.5 million by 2035, registering a CAGR of 9.8% during the forecast period (2026–2035). The increasing global burden of obesity continues to play a central role in shaping demand for herbal weight loss products across multiple consumer segments. According to the World Health Organization, one in eight people were living with obesity in 2022, while adult obesity has more than doubled since 1990 and adolescent obesity has quadrupled, reflecting a sustained rise in lifestyle-related health concerns. WHO data further indicates that 2.5 billion adults were overweight in 2022, including nearly 890 million living with obesity, with 43% of adults aged 18 years and above classified as overweight and 16% living with obesity. These figures indicates growing public health pressure to adopt preventive wellness approaches, encouraging consumers to explore plant-based formulations such as tea extract, ginger/turmeric, moringa, and apple cider vinegar. Increased awareness of metabolic health risks is influencing purchasing patterns toward herbal capsules, powders, and liquid extracts positioned around natural weight management.

Focal segmental glomerulosclerosis market was valued at $1,208.0 million in 2025 and is anticipated to reach $2,100.6 million by 2035, registering a CAGR of 5.8% over the forecast period from 2026 to 2035. The growth of the focal segmental glomerulosclerosis (FSGS) market is strongly linked to the increasing burden of chronic kidney disease, which expands the patient population requiring long-term pharmacological management and renal replacement therapies. According to US Centers for Disease Control and Prevention, more than 35.5 million adults in the US, or nearly 14% of the adult population, are living with chronic kidney disease, while as many as nine in ten individuals remain unaware of their condition.